EuBiologics Co Ltd
KOSDAQ:206650
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
EuBiologics Co Ltd
Net Income (Common)
EuBiologics Co Ltd
Net Income (Common) Peer Comparison
068270
302440
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
E
|
EuBiologics Co Ltd
KOSDAQ:206650
|
Net Income (Common)
-₩17.4B
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Net Income (Common)
₩392.8B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Net Income (Common)
₩22.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Net Income (Common)
₩97.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Net Income (Common)
₩76.1B
|
CAGR 3-Years
24%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
A
|
Alteogen Inc
KOSDAQ:196170
|
Net Income (Common)
₩25.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is EuBiologics Co Ltd's Net Income (Common)?
Net Income (Common)
-17.4B
KRW
Based on the financial report for Mar 31, 2024, EuBiologics Co Ltd's Net Income (Common) amounts to -17.4B KRW.
What is EuBiologics Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
37%
Over the last year, the Net Income (Common) growth was -3 146%. The average annual Net Income (Common) growth rates for EuBiologics Co Ltd have been 37% over the past three years .
You don't have any saved screeners yet
